Moreover, methylation levels of the APOE gene have been frequently investigated in the peripheral blood of patients in the early stages of AD, and all the studies performed so far identified differential methylation between MCI or presymptomatic dementia patients and the control group, suggesting its usefulness as an early biomarker for AD [21,64,65]. This evidence concerns the gene APOE and Alzheimer disease.